Friday, 11th February 34th Lorne Cancer Conference 2022

• Target gene-independent functions of MYC - Martin Eilers
• Cancer evolution in the surrounding microenvironment and in response to immunotherapy - Francesca Ciccarelli
• Genome wide CRISPR/Cas9 knockout screens in vivo identify GATOR1 components as tumour suppressors in Eμ-Myc lymphoma development      - Margaret A Potts
• From functional genomics to precision medicine: targeting the dynamic cellular ecosystem of pancreatic cancer using clinically-safe agents  - Sean Porazinski
• Control of mitotic cell death by tumour suppressors, oncogenes and cancer chemotherapeutic drugs - Paul Clarke

• Spatial Multi-Omics Sequencing at Tissue Scale and Cellular Level - Rong Fan
• Solid tumours as cellular ecosystems: new insights into disease stratification and treatment - Alex Swarbrick
• A novel Src-FRET biosensor mouse providing real-time insights into the dynamic spatiotemporal regulation of Src activity in healthy and diseased contexts. - David Herrmann
• Targeting the Tuft cells-Type 2 Innate Lymphoid Cell cytokine circuit in Gastric Cancer - Ryan O'Keefe

Prof Clare Scott
Joint Division Head of Clinical Translation, Walter and Eliza Hall Institute of Medical Research (WEHI)
’Precision oncology in rare gynaecological cancers: how to make a difference to patient outcomes’

Development of recombinant immunotherapeutic antibody with GenScript’s next generation proprietary CHO expression platform

Speaker: Dr. Hui Foon Tan, Product Manager, GenScript

Abstract:

The high prevalence of cancer and the unmet needs for cancer treatment have contributed to the rapid growth of cancer treatment discovery. Scientists are looking for an effective strategy to overcome the current treatment hurdles by understanding the interactions of cancer and immune system. Immunotherapy employs patients’ immune system to combat cancer with lesser side effects compared to the traditional treatments. In recent years, increasing number of cancer researches on recombinant therapeutic antibody have made the development of immunotherapy more efficient. Additionally, the emerging of novel bispecific antibody with dual targets binding functionalities in one drug has increased the therapeutic efficacy and improved the limitations of recombinant antibody.

In this meeting, I shall discuss the interactions of immune system and cancer, the development of recombinant immunotherapeutic antibodies in cancer treatment, the common challenges in recombinant antibody production the scientists faced today and lastly, how could our GenScript’s next generation proprietary CHO expression platform solve these problems.

• Genetics, epigenetics and immunotherapy of checkpoint inhibitor resistant melanoma - Jonas Nilsson
• Rethinking preclinical testing for paediatric brain cancers – is there a better way? - Raelene Endersby
• Intravital imaging reveals novel bone and tumour cell interactions: Implications for bone targeted therapeutic control of metastatic growth. - Michelle McDonald
• Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status - Kendelle J Murphy
• The kinase activity of the cancer stem cell marker DCLK1 orchestrates pro-tumorigenic stromal changes - Michael Buchert

• A Novel Peptide-MHC Targeted Chimeric Antigen Receptor T Cell forms a T Cell-like Immune Synapse - Kylie Luong
• Functional Genomic Screening to Identify Mechanisms of Platinum Resistance in Small Cell Lung Cancer - Quinton Luong
• Cytoplasmic JNK activity promotes metastasis in triple negative breast cancer - Sophie A Lynn
• First-time-in-human imaging with a novel PD-L1 PET tracer in patients with lung cancer - Michael MacManus
• On target; an orthotopic intrapulmonary (iPUL) delivery method for focal lung tumour formation in vivo - Jackson A McDonald
• Porcupine inhibition as a strategy for personalised therapy in pancreatic adenocarcinoma - Benjamin McLean
• Profiling macrophages and their function in early breast cancer tumor microenvironment - Ibraheem Nasir
• Interrogating the heterogeneity of human small cell lung cancer using single cell technologies - Jin Ng
• Deconvolution of transcriptional programs contributing to chemoresistance in neuroblastoma patient tumours at a single-cell resolution - Sin Wi Ng
• Plant-derived extracellular nanovesicle as a multifunctional nanocarrier targeting cancer cells - Tuong Nguyen
• Loss of Keap1 triggers Nrf2-mediated aberrant lysosomal biogenesis and post-developmental lethality - Athena S Ong
• The role of BTN2A1 in cancer - Simone Ostrouska
• Heterogeneity and function of mammary gland fibroblasts - Rosa Pascual
• An optimised syngeneic melanoma mouse model -  YUMMER1.7-PV1 for the assessment of sequencing targeted therapies and immunotherapies - Riyaben P Patel
• Developing a novel intraoperative diagnosis method for cancer surgery - Shweta Patel
• Dual spatial assessment of contemporary patient pancreatic tumours via spatial transcriptomics and MALDI mass spectrometry imaging - Brooke Pereira
• Improving the therapeutic targeting of high-grade serous ovarian cancer - Zoe Phan
• The role of eukaryotic elongation factor kinase 2 (eEF2K) in breast cancer progression.  - Valentina VP Poltavets
• Disabled-2 (DAB2), a novel target of Hyaluronan (HA) signalling in ovarian cancer  - Zoe Price
• Multispectral immunohistochemical immune profiling of patients with rare gynaecological malignancies and high mutational burden - Luke T Quigley
• Development of targeted epigenetic combination therapies for the treatment of neuroblastoma - DAENIKKA RAVINDRARAJAH
• Dual epithelial and stromal targeting in breast cancer using ROCK2 inhibition: Guiding chemotherapy and anti-metastatic response via intravital imaging - Daniel A Reed
• A multi-omics approach to dissect the impact of the cancer secretome during pancreatic cancer progression. - Shona Ritchie
• Pathogenic Variants in Hereditary Cancer Syndrome Genes are Prevalent Among Breast Cancer Patients Not Meeting Various International Genetic Testing Guidelines - Nandor Roczo
• TRIP13 as a candidate therapeutic target in Mucinous Ovarian Carcinoma - Rita Saoud
• Harnessing the Full Potential of T cells for Adoptive Cell Transfer - Terri Scanlon
• Comprehensive analysis of structural variants in clinical cancer samples - Azadeh Seidi
• Identifying cell of origin in high grade serous ovarian cancer using gene expression data - Masih Sherafatian
• Identification of therapeutic vulnerabilities in Atypical Teratoid Rhabdoid Tumours - Hui (Claire) Shi
• Characterising therapy-induced senescence to identify novel targeting approaches in high-grade serous ovarian cancer. - Madeleine R Tancock
• Immunostaging to improve the prediction of recurrence in stage III melanoma patients - Elnaz Tavancheh
• Surprisingly, pro-survival MCL-1 is not essential for haematopoietic development - Annli Tee
• Fluorescent reporter mice for p53 target genes to investigate p53-mediated tumour suppression. - Annabella Thomas
• Amino acid withdrawal regulates tumour immune escape through MEX3C-dependent downregulation of MHC class I - Keziah E Ting
• Pinpointing and targeting novel drivers of pancreatic cancer progression and metastasis using TRAP-seq. - Michael Trpceski
• ATF4-dependent induction of NNMT is a key regulator of cancer-associated fibroblast activation and function - Srimayee Vaidyanathan
• Inhibition or targeting of EphA3 receptor tyrosine kinase expression in perivascular myofibroblast-like stromal cells inhibits tumour growth - Mary E Vail
• The microtubule inhibitor eribulin demonstrates efficacy in platinum resistant and refractory high-grade serous ovarian cancer patient derived xenograft models - Cassandra Vandenberg
• Complementing whole genome sequencing with whole transcriptome sequencing in precision oncology - Leila N Varghese
• Scalable and Highly Sensitive Single Cell RNA-seq through Combinatorial Barcoding   - Jiyoti Verma
• Using CRISPR activation CROP-seq techniques to mimic signals from the microenvironment that mediate resistance to venetoclax in aggressive lymphomas - Gaoyuan Wang
• Cytolinker plakins are lost in high-grade serous ovarian cancer - exploring links to epithelial-mesenchymal transition - Tamsin Wesley
• Tissue remodelling shapes the tumour immune microenvironment in glioma and GBM - Samuel Widodo
• Interrogating the extracellular matrix in pancreatic ductal adenocarcinoma (PDAC) stroma to identify novel targets for stromal normalisation strategies - Kaitlin Wyllie
• The role of the ADAM10 metalloprotease in cancer and it’s utility as a drug target - Hengkang Yan
• Mammary tumour cells remodel the bone marrow vascular microenvironment to support metastasis - Raymond Yip
• Overcoming CDK4/6 inhibitor resistance in breast cancer by CDK1 targeting revealed by the CDK1-FRET mouse - Clare Zhang
• Evaluation of clonality in lentigo maligna - Peinan Zhao
• The role of Mediator kinase in regulating intestinal homeostasis and colorectal cancer - Danxi Zhu
• Whole genome and transcriptome sequencing to inform challenging cancer diagnoses: The pathologist-initiated COLUMN study. - Joseph H.A. Vissers
• mRNA - A Game Changer For Vaccines - Selva Kumari Ramasubramanian
• Investigating differential methylation of molecular markers in Pediatric astrocytoma - Dona Johns